MA39342A1 - Anticorps il -21 - Google Patents

Anticorps il -21

Info

Publication number
MA39342A1
MA39342A1 MA39342A MA39342A MA39342A1 MA 39342 A1 MA39342 A1 MA 39342A1 MA 39342 A MA39342 A MA 39342A MA 39342 A MA39342 A MA 39342A MA 39342 A1 MA39342 A1 MA 39342A1
Authority
MA
Morocco
Prior art keywords
antibodies
methods
compositions
antagonism
neutralize
Prior art date
Application number
MA39342A
Other languages
English (en)
Other versions
MA39342B2 (fr
Inventor
Julian Davies
Fabio Magrini
Andrea Paula Martin
Neelufar Mozaffarian
Chetankumar Natvarlal Patel
Oliver Schroeder
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA39342A1 publication Critical patent/MA39342A1/fr
Publication of MA39342B2 publication Critical patent/MA39342B2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des anticorps humanisés construits qui ont une forte affinité de liaison pour il -21 humain et qui le neutralisent, des procédés d'utilisation desdits anticorps pour traiter des maladies dans lesquelles l'antagonisme ou la neutralisation des effets d'il -21 est garanti, telles que des maladies auto-immunes, des compositions et des procédés de production par recombinaison des anticorps, et des compositions pharmaceutiques comprenant lesdits anticorps.
MA39342A 2014-03-21 2015-03-13 Anticorps il -21 MA39342B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461968550P 2014-03-21 2014-03-21
PCT/US2015/020383 WO2015142637A1 (fr) 2014-03-21 2015-03-13 Anticorps il -21

Publications (2)

Publication Number Publication Date
MA39342A1 true MA39342A1 (fr) 2018-03-30
MA39342B2 MA39342B2 (fr) 2020-03-31

Family

ID=54141466

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39342A MA39342B2 (fr) 2014-03-21 2015-03-13 Anticorps il -21

Country Status (24)

Country Link
US (1) US9394362B2 (fr)
EP (1) EP3119806B1 (fr)
JP (2) JP6053989B2 (fr)
KR (1) KR101859857B1 (fr)
CN (1) CN106061999B (fr)
AP (1) AP2016009450A0 (fr)
AR (1) AR099625A1 (fr)
AU (1) AU2015231777B2 (fr)
BR (1) BR112016019176A2 (fr)
CA (1) CA2939543C (fr)
CL (1) CL2016002281A1 (fr)
EA (1) EA033335B1 (fr)
EC (1) ECSP16075416A (fr)
ES (1) ES2774422T3 (fr)
IL (1) IL246909A0 (fr)
MA (1) MA39342B2 (fr)
MX (1) MX2016012120A (fr)
MY (1) MY177915A (fr)
NZ (1) NZ722518A (fr)
PE (1) PE20161221A1 (fr)
PH (1) PH12016501820A1 (fr)
SG (1) SG11201606705QA (fr)
TW (1) TWI646105B (fr)
WO (1) WO2015142637A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015157238A2 (fr) 2014-04-08 2015-10-15 Medimmune, Llc Molécules de liaison spécifiques de l'il-21 et leurs utilisations
US10654932B2 (en) * 2015-10-30 2020-05-19 Genentech, Inc. Anti-factor D antibody variant conjugates and uses thereof
WO2017172509A1 (fr) * 2016-03-31 2017-10-05 Eli Lilly And Company Anticorps contre il-21 et leurs utilisations
CA3108282A1 (fr) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Complexes de ciblage musculaire et leurs utilisations pour le traitement de dystrophinopathies
KR20220020879A (ko) 2019-06-12 2022-02-21 에스크진 파마, 아이엔씨. 새로운 il-15 프로드럭 및 이를 사용하는 방법
US20220289822A1 (en) 2019-08-21 2022-09-15 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2023283624A2 (fr) * 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Complexes de ciblage musculaire et leurs utilisations dans le traitement de dystrophinopathies
IL309937A (en) * 2021-07-09 2024-03-01 Dyne Therapeutics Inc Muscle targeting complexes and their uses for the treatment of dystrophinopathy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI9715219B8 (pt) * 1996-02-09 2015-07-07 Abbvie Biotechnology Ltd Vetor recombinante de expressão, e célula hospedeira procariótica.
AU2004221876B2 (en) * 2003-03-14 2011-05-26 Cambridge Antibody Technology Limited Antibodies against human IL-21 receptor and uses therefor
ITRM20040586A1 (it) * 2004-11-29 2005-02-28 Giuliani Spa Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico.
EP1963369B1 (fr) * 2005-11-28 2013-05-15 Zymogenetics, Inc. Antagonistes de l'il-21
WO2007114861A2 (fr) * 2005-11-28 2007-10-11 Zymogenetics, Inc. Antagonistes du recepteur de il-21
US20090076249A1 (en) 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
KR101615215B1 (ko) * 2007-12-07 2016-04-25 지모제넥틱스, 인코포레이티드 항-사람 ｉｌ-21 단클론성 항체
CN101970488B (zh) * 2007-12-07 2014-06-18 津莫吉尼蒂克斯公司 对il-31特异的人源化抗体分子
US20130323259A1 (en) 2011-01-17 2013-12-05 Novo Nordisk A/S Il-21 ligands
EP2714198A1 (fr) * 2011-05-31 2014-04-09 Novo Nordisk A/S Epitopes de il-21 et ligands de il-21

Also Published As

Publication number Publication date
EA201691521A1 (ru) 2017-02-28
CL2016002281A1 (es) 2017-06-23
JP2016520088A (ja) 2016-07-11
CA2939543A1 (fr) 2015-09-24
CN106061999B (zh) 2020-07-31
NZ722518A (en) 2017-12-22
IL246909A0 (en) 2016-09-29
EP3119806A1 (fr) 2017-01-25
US20150266954A1 (en) 2015-09-24
MY177915A (en) 2020-09-25
PH12016501820A1 (en) 2016-11-07
EP3119806A4 (fr) 2017-11-01
AU2015231777B2 (en) 2017-08-03
CA2939543C (fr) 2018-01-16
JP6053989B2 (ja) 2017-01-11
WO2015142637A1 (fr) 2015-09-24
AU2015231777A1 (en) 2016-08-18
SG11201606705QA (en) 2016-09-29
BR112016019176A2 (pt) 2017-10-10
MA39342B2 (fr) 2020-03-31
KR101859857B1 (ko) 2018-05-18
US9394362B2 (en) 2016-07-19
TW201623330A (zh) 2016-07-01
CN106061999A (zh) 2016-10-26
TWI646105B (zh) 2019-01-01
JP6373944B2 (ja) 2018-08-15
ECSP16075416A (es) 2018-05-31
EA033335B1 (ru) 2019-09-30
ES2774422T3 (es) 2020-07-21
EP3119806B1 (fr) 2020-01-01
AP2016009450A0 (en) 2016-09-30
MX2016012120A (es) 2016-12-09
AR099625A1 (es) 2016-08-03
JP2017093435A (ja) 2017-06-01
KR20160124166A (ko) 2016-10-26
PE20161221A1 (es) 2016-11-12

Similar Documents

Publication Publication Date Title
MA39342A1 (fr) Anticorps il -21
WO2016191643A3 (fr) Agents de liaison à tigit et leurs utilisations
MA44322A (fr) Compositions comprenant des souches bactériennes
MA42471A (fr) Compositions comprenant des souches bactériennes
MA40755B1 (fr) Compositions comprenant des souches bactériennes
CL2018003582A1 (es) Composiciones para modular la expresión de c9orf72 (divisional solicitud 201702567)
MX2020001513A (es) Agentes de union a clec9a y su uso.
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
WO2017106346A3 (fr) Anticorps neutralisants le virus de l'immunodéficience humaine
MA41013B1 (fr) Compositions comprenant des souches bactériennes
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA201791485A1 (ru) Анти-cd47-антитела и их применения
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
WO2017214170A3 (fr) Anticorps baff-r et utilisations de ceux-ci
WO2015171558A3 (fr) Benzènesulfonamido et composés apparentés utilisés en tant qu'agonistes de rorγ et pour le traitement de maladie
MX2019003805A (es) Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
MX2023000204A (es) Variantes de proteinas de union al factor h y metodos de uso de estas.
EA201790773A1 (ru) Композиции и способы для ингибирования биологической активности растворимых биомолекул
MX2021005085A (es) Formulacion de anticuerpo.
WO2016020882A3 (fr) Anticorps de type angiopoétine 4 (angptl4) et procédés d'utilisation
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
WO2017044866A3 (fr) Administration améliorée de médicaments au cerveau
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
MX2019014448A (es) Inmunoglobulinas de enlace a mmp13.